No difference seen in change in median tibial cartilage volume at 12 months for platelet-rich plasma versus saline placebo injections
FRIDAY, Dec. 3, 2021 (HealthDay News) — For patients with symptomatic mild-to-moderate radiographic knee osteoarthritis (OA), intra-articular injections of platelet-rich plasma (PRP) do not significantly improve knee pain or reduce median tibial cartilage volume loss at 12 months compared with saline placebo injection, according to a study published in the Nov. 23/30 issue of the Journal of the American Medical Association.
Kim L. Bennell, Ph.D., from the University of Melbourne in Australia, and colleagues examined the effects of intra-articular PRP injections on symptoms and joint structure among 288 patients aged 50 years and older with symptomatic medial knee OA. Interventions in this randomized clinical trial included three intra-articular injections at weekly intervals of either leukocyte-poor PRP or saline (144 participants in each group).
Ninety-seven percent of the participants in both groups received all three injections. The researchers found that treatment with PRP versus placebo injection resulted in a mean change in knee pain scores of â2.1 and â1.8 points, respectively, after 12 months. The mean change in medial tibial cartilage volume was â1.4 and â1.2 percent, respectively, for treatment with PRP versus placebo injection. Twenty-nine of the 31 prespecified secondary outcomes showed no significant between-group differences.
“These findings do not support use of PRP for the management of knee OA,” the authors write.
One author disclosed financial ties to the biopharmaceutical industry; a second author disclosed ties to the publishing and medical technology industries.
Copyright © 2021 HealthDay. All rights reserved.